bioMérieux buys Accellix to boost cell and gene therapy quality control
PARIS: French diagnostics group bioMérieux said on Thursday it has acquired U.S.-based Accellix, a developer of rapid, automated flow cytometry platforms, in a deal worth around €35 million. The acquisition strengthens bioMérieux’s pharmaceutical quality control business and expands its portfolio of solutions for advanced therapies, including cell and gene treatments. Accellix’s compact platform delivers results…